Carboplatin Treatment for Children's Tumors
Author Information
Author(s): C.R. Pinkerton, V. Broadbent, A. Horwich, J. Levitt, T.J. McElwain, S.T. Meller, M. Mott, A. Oakhill, J. Pritchard
Primary Institution: The Royal Marsden Hospital
Hypothesis
Can a carboplatin-based regimen effectively treat malignant germ cell tumors in children?
Conclusion
The JEB regimen is effective and well-tolerated, showing comparable efficacy to cisplatin-based treatments with less toxicity.
Supporting Evidence
- Complete marker response was achieved in 19 out of 19 evaluable patients.
- Complete remission of measurable tumor occurred in 16 out of 19 patients.
- The regimen was well tolerated apart from myelosuppression.
- Three patients relapsed, but two remain in second complete remission after further treatment.
- One death was attributed to probable bleomycin pulmonary toxicity.
Takeaway
This study tested a new treatment for kids with certain tumors, and it worked well without causing too much harm.
Methodology
21 children aged 1 to 16 years received the JEB regimen, which included carboplatin, etoposide, and bleomycin, with doses adjusted based on renal function.
Limitations
The study had a small sample size and lacked a control group for comparison.
Participant Demographics
Children aged 1 to 16 years, with a median age of 11 years.
Want to read the original?
Access the complete publication on the publisher's website